Abstract
After two years of gradual revelations concerning undisclosed information on suicidal risks to children on antidepressants, a federal advisory committee in Sep 2004 recommended that such drugs be labeled to alert physicians and consumers of this risk. The antidepressant story is noteworthy in its own right, shedding light on the tangled web of legal, regulatory, economic, and ethical issues surrounding disclosure practices in the pharmaceutical industry. The complex interworkings of an emerging global economy make it necessary for corporate standards for disclosure to be established and enforced.
Citation
Allen L. White,
Why We Need Global Standards for Corporate Disclosure,
69 Law and Contemporary Problems
167-186
(Summer 2006)
Available at: https://scholarship.law.duke.edu/lcp/vol69/iss3/9